News
GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...
Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.
AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...
In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...
Sitamraju Sree Ramakrishna, manager projects, at GlaxoSmithKline Consumer Healthcare’s (GSKCH) Rajahmundry factory, raised a ...
With half a million people having already received multi-cancer early detection (MCED) screening, patients are and will continue to be asking about these blood tests during their visits, physicians ...
Hiding the Truth, from Farm to Fable,” reveals how the animal agriculture industry shielded itself from scrutiny.
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...
Antibiotic innovation, rising female UTI cases, and diagnostic advances are key drivers shaping the future of the UTI market. CA, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- Urinary tract ...
In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis AG, with a price target of CHF89.00. The company’s shares opened today at CHF97.91. According to ...
In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $108.00. The company’s shares closed yesterday at $122.94. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results